The US Food and Drug Administration has cleared Roche and partner Eli Lilly’s blood test to help identify signs of Alzheimer’s disease in people age 55 and older with cognitive decline.
Live TV
Listen
Watch
US
International
FDA Clears New Alzheimer’s Blood Test
FDA clears Roche and Eli Lilly Alzheimer's blood test
Correction to Roche Flash Headlines
Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
Alzheimer: un test sanguin de Roche et Eli Lilly approuvé pour la commercialisation aux États-Unis
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
FDA Clears Blood Test to Detect Alzheimer's in Primary and Specialty Care
FDA clears PrecivityAD2, Alzheimer's disease blood test for as early as age 40 years
Exame sanguíneo para Alzheimer desenvolvido pela Roche e Eli Lilly é aprovado por agência dos EUA
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
The new test promises to be “minimally invasive” and can help doctors identify symptoms of Alzheimer’s disease earlier.
The Elecsys pTau217 test can help doctors assess amyloid pathology in people 55 and older showing signs of cognitive decline
Roche received U.S. FDA approval for an Alzheimer's disease blood test. "Roche Gets FDA Clearance Alzheimer's Disease Drug" and…
The U.S. Food and Drug Administration has cleared another blood test that could help doctors identify whether memory problems are…
Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
Après l'Europe, le test sanguin des entreprises pharmaceutiques Roche et Eli Lilly a été approuvé pour la commercialisation par…
